琥珀酸美托洛尔缓释片与酒石酸美托洛尔片对COPD并CHF患者预后的影响比较

摘要

目的 探讨两种美托洛尔片在慢性阻塞性肺疾病(COPD)并慢性心力衰竭(CHF)患者中的治疗价值.方法 纳入本院收治的COPD并CHF患者60例,按数字随机表分成A组、B组,各30例.A组为琥珀酸美托洛尔缓释片治疗,B组予以酒石酸美托洛尔片治疗,比较两组治疗效果、心功能及不良反应.结果 A组有效率为96.67％,较B组的80.00％高,两组比较差异有统计学意义(P＜0.05);A组治疗后的LVEF低于B组,LVEDD、LVESD较B组高(均P＜0.05);A组不良反应率(6.67％)较B组(10.00％)低,差异无统计学意义(P＞0.05).结论 与酒石酸美托洛尔比较,琥珀酸美托洛尔缓释片效果更显著,能促进心功能进一步改善,值得临床推广.%Objective To investigate the therapeutic values of two types of metoprolol tablets for chronic obstructive pulmonary disease (COPD) complicating with chronic heart failure (CHF) and observe the patients' prognosis.Methods 60 patients with COPD and CHF treated at our hospital were randomly divided into group A (30 cases) and group B (30 cases).Group A were treated with Metoprolol succinate sustained-release tablets and group B metoprolol tartrate tablets.The therapeutic effects,cardiac function,and adverse reactions in the two groups were compared.Results The effective rate was 96.67％ ingroup A and was 80.00％ in group B,with a statistical difference (P ＜ 0.05).After the treatment,the LVEF was lower and the LVEDD and LVESD higher in group A than in group B (all P ＜ 0.05).The incidence of adverse reactions was lower in group A than in group B (6.67％ vs.10.00％),but with no statistical difference (P ＞ 0.05).Conclusion Compared with metoprolol tartrate tablets,metoprolol succinate sustained-release tablets is more effective and can promote further improvement of cardiac function,so it is worth being clinically generalized.